Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Contact Us

Contact Exact Sciences for more information about Oncotype DX® and Oncomap™ tests.

You may unsubscribe at any time. If you provide your phone number, we will not use your phone number for marketing purposes, or share with third parties; we will only use your phone number to reply to a question you have asked. We will not sell information you provide here to third parties.

Global Contact

United States, Canada
+1 866-662-6897
Email Customer Service

Europe, Middle East, Africa
+41 22 715 29 00
Email European Support

Asia Pacific, Latin America
+1 866-662-6897
Email International Customer Support